Fundraising FoxRegeneron Ventures — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.
BiotechHealthtech
Rachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)inWilliam LaRochelle(Chief Scientific Officer)inStacy M. Plum(Chief Technology Officer)
Co-investorsSanofi VenturesTaiho Ventures, LLCPfizer VenturesSamsara BioCapitalCanaan PartnersConnecticut Innovations+6 more
Develops programmable mRNA therapies that last longer and target cells more precisely for cancer and other diseases.
BiotechBoston, US
Tasuku Kitada(Executive Officer, Director, Promoter)inJacob Becraft(Executive Officer, Director, Promoter)inSamta Kundu(Executive Officer)in
BoardJeb Keiper(Director)inAla Alenazi(Director)inPegah Ebrahimi(Director)in
Co-investorsJIC Venture Growth InvestmentsKinnevikPlayground GlobalAmgen VenturesANRIFPV+3 more
Strand is a clinical-stage biotechnology company developing programmable mRNA therapeutics for cancers and autoimmune diseases.
AI & Machine LearningBiotechMedical DevicesBoston, US
Jacob Becraft(CEO, Co-Founder)inTasuku Kitada(President, Head of R&D, Co-founder)inRon Weiss(Scientific Co-founder)inDarrell J. Irvine(Scientific Co-founder)inPrashant Nambiar(Chief Scientific Officer)Ethan Cash(Senior Vice President, Head of Portfolio Management and Program Development)in
Co-investorsAtinum Investment Co. Ltd.FPVLG Technology VenturesPlayground GlobalPotentum PartnersAlix Ventures+5 more
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Co-Founder, President, CFO, COO)inDerek Jantz(Executive Officer)inCharles Gersbach(Co-Founder)inJohn McHutchison(CEO, Chairman of the Board)inDan McHugh(Co-Founder, Investor)inBlythe Sather(Executive Officer)in
Co-investorsDuke Capital PartnersHatteras Venture PartnersMission BiocapitalNew Enterprise Associates (NEA)Pappas CapitalRV Invest GmbH+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.